PL376713A1 - Zastosowanie pochodnych kwasu piperazynosulfonowego jako antagonistów CCR1 do leczenia zwłóknienia, choroby Alzheimera i innych zaburzeń - Google Patents
Zastosowanie pochodnych kwasu piperazynosulfonowego jako antagonistów CCR1 do leczenia zwłóknienia, choroby Alzheimera i innych zaburzeńInfo
- Publication number
- PL376713A1 PL376713A1 PL376713A PL37671303A PL376713A1 PL 376713 A1 PL376713 A1 PL 376713A1 PL 376713 A PL376713 A PL 376713A PL 37671303 A PL37671303 A PL 37671303A PL 376713 A1 PL376713 A1 PL 376713A1
- Authority
- PL
- Poland
- Prior art keywords
- fibrosis
- disorders
- treatment
- sulfonic acid
- acid derivatives
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- BHJHVDDOCMGCDD-UHFFFAOYSA-N piperazin-1-ium-1-sulfonate Chemical class OS(=O)(=O)N1CCNCC1 BHJHVDDOCMGCDD-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42257302P | 2002-10-30 | 2002-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL376713A1 true PL376713A1 (pl) | 2006-01-09 |
Family
ID=32230371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL376713A PL376713A1 (pl) | 2002-10-30 | 2003-10-20 | Zastosowanie pochodnych kwasu piperazynosulfonowego jako antagonistów CCR1 do leczenia zwłóknienia, choroby Alzheimera i innych zaburzeń |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040116441A1 (pl) |
| EP (1) | EP1558258A1 (pl) |
| JP (1) | JP2006506394A (pl) |
| CN (1) | CN1708304A (pl) |
| AU (1) | AU2003269381A1 (pl) |
| BR (1) | BR0315762A (pl) |
| CA (1) | CA2500850A1 (pl) |
| MX (1) | MXPA05004652A (pl) |
| PL (1) | PL376713A1 (pl) |
| TW (1) | TW200412963A (pl) |
| WO (1) | WO2004039377A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2585983C (en) * | 2004-11-10 | 2014-03-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| JP5731538B2 (ja) | 2009-12-23 | 2015-06-10 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Ｃｒｔｈ２モジュレーター |
| WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| SI2938597T1 (sl) * | 2012-12-27 | 2017-03-31 | Alzprotect | Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h- benzo(d)imidazol-2-amin, njihova priprava in uporaba istega |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (pl) * | 1962-12-19 | |||
| US4060598A (en) * | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| CN1450999A (zh) * | 2000-03-31 | 2003-10-22 | 辉瑞产品公司 | 新的哌嗪衍生物 |
| SK15722003A3 (sk) * | 2001-06-20 | 2004-08-03 | Pfizer Products Inc. | Deriváty kyseliny sulfónovej a ich použitie |
-
2003
- 2003-10-16 US US10/687,110 patent/US20040116441A1/en not_active Abandoned
- 2003-10-20 WO PCT/IB2003/004642 patent/WO2004039377A1/en not_active Ceased
- 2003-10-20 PL PL376713A patent/PL376713A1/pl not_active Application Discontinuation
- 2003-10-20 CA CA002500850A patent/CA2500850A1/en not_active Abandoned
- 2003-10-20 MX MXPA05004652A patent/MXPA05004652A/es not_active Application Discontinuation
- 2003-10-20 AU AU2003269381A patent/AU2003269381A1/en not_active Abandoned
- 2003-10-20 BR BR0315762-8A patent/BR0315762A/pt not_active Application Discontinuation
- 2003-10-20 EP EP03751162A patent/EP1558258A1/en not_active Withdrawn
- 2003-10-20 JP JP2004547885A patent/JP2006506394A/ja active Pending
- 2003-10-20 CN CNA2003801022667A patent/CN1708304A/zh active Pending
- 2003-10-29 TW TW092130081A patent/TW200412963A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003269381A1 (en) | 2004-05-25 |
| TW200412963A (en) | 2004-08-01 |
| MXPA05004652A (es) | 2005-06-08 |
| EP1558258A1 (en) | 2005-08-03 |
| CN1708304A (zh) | 2005-12-14 |
| US20040116441A1 (en) | 2004-06-17 |
| BR0315762A (pt) | 2005-09-20 |
| CA2500850A1 (en) | 2004-05-13 |
| JP2006506394A (ja) | 2006-02-23 |
| WO2004039377A1 (en) | 2004-05-13 |
| WO2004039377A8 (en) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003004480A3 (en) | Substituted piperazine and diazepanes as histamine h3 receptor agonists | |
| TWI369987B (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
| WO2007002293A3 (en) | Azaindazole compounds and methods of use | |
| IL163102A (en) | Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders | |
| IL219397A0 (en) | Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same | |
| SI1656346T1 (sl) | 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni | |
| IS7840A (is) | 3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum | |
| UA85597C2 (ru) | Четвертичные соли как антагонисты ccr2 | |
| IL210046A0 (en) | Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease | |
| WO2005056547A3 (en) | Quinoxalines useful as inhibitors of protein kinases | |
| PL358306A1 (pl) | Związki o aktywności agonistycznej 5-HT1A użyteczne w leczeniu zaburzeń zewnętrznej siatkówki | |
| AU2003269364A1 (en) | Use of piperazine derivatives as ccr1 antagonists | |
| WO2007044885A3 (en) | Piperidine derivatives and methods of use | |
| PT1487828E (pt) | Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias | |
| NO20055098D0 (no) | Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser | |
| PL370746A1 (pl) | Pochodne piperazyny do stosowania jako antagoniści receptora CCR-3 w leczeniu astmy | |
| PL376713A1 (pl) | Zastosowanie pochodnych kwasu piperazynosulfonowego jako antagonistów CCR1 do leczenia zwłóknienia, choroby Alzheimera i innych zaburzeń | |
| AU2003238046A1 (en) | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease | |
| DK1309322T3 (da) | Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser | |
| PT1569627E (pt) | Método de tratamento de doenças do movimento utilizando derivados do ácido barbitúrico | |
| HUP0204391A3 (en) | The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders | |
| IL166226A0 (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders | |
| AU2003294100A8 (en) | Use of hyaluronic acid for respiratory disorders or the upper airways | |
| ZA200503417B (en) | Use of piperazine sulfonic acid derivatives as CCR1 antagonists for the treatment of fibrosis, Alzheimer disease and other disorders | |
| ZA200108289B (en) | Use of osanetant in the production of medicaments used to treat mood disorders. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |